Penumbra, Inc. (NYSE:PEN) Files An 8-K Results of Operations and Financial Condition

Penumbra, Inc. (NYSE:PEN) Files An 8-K Results of Operations and Financial Condition
Item 2.02.

Story continues below

Results of Operations and Financial Condition.

On August 8, 2017, Penumbra, Inc. issued a press release announcing financial results for the second fiscal quarter ended June30, 2017. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information furnished on this Current Report on Form 8-K, including the attached exhibit, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 2.02.

Financial Statements and Exhibits.

Exhibit Number

Description

99.1

Press release of Penumbra, Inc. dated August 8, 2017.


Penumbra Inc Exhibit
EX-99.1 2 pen-063017xexhibit991.htm EXHIBIT 99.1 Exhibit Exhibit 99.1 Penumbra,…
To view the full exhibit click here

About Penumbra, Inc. (NYSE:PEN)

Penumbra, Inc. (Penumbra) is an interventional therapies company. The Company designs, develops, manufactures and markets medical devices. The Company has a portfolio of products that addresses medical conditions and significant clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. The Company focuses on developing, manufacturing and marketing products for use by specialist physicians, including interventional neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists and vascular surgeons. Its neuro products include Neurovascular Access, Ischemic Stroke, Neurovascular Embolization and Neurosurgical Tools. The Company’s peripheral vascular products include Peripheral Embolization and Peripheral Thrombectomy.

An ad to help with our costs